Department of Drug Science and Technology

Selected research products

Gastaldi S, Rocca C, Gianquinto E, Granieri MC, Boscaro V, Blua F, Rolando B, Marini E, Gallicchio M, De Bartolo A, Romeo N, Mazza R, Fedele F, Pagliaro P, Penna C, Spyrakis F, Bertinaria M, Angelone T. (2023) Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation. European journal of medicinal chemistry 257 115542 [DOI  PMID]

Boscaro V, Rivoira M, Sgorbini B, Bordano V, Dadone F, Gallicchio M, Pons A, Benetti E, Rosa AC. (2022) Evidence-Based Anti-Diabetic Properties of Plant from the Occitan Valleys of the Piedmont Alps. Pharmaceutics 14(11) [DOI  PMID]

Boscaro V, Barge A, Deagostino A, Ghibaudi E, Laurenti E, Marabello D, Diana E, Gallicchio M. (2021) Effects of Vanadyl Complexes with Acetylacetonate Derivatives on Non-Tumor and Tumor Cell Lines. Molecules (Basel, Switzerland) 26(18) [DOI  PMID]

Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. (2021) Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules (Basel, Switzerland) 26(13) [DOI  PMID]

Lolli ML, Carnovale IM, Pippione AC, Wahlgren WY, Bonanni D, Marini E, Zonari D, Gallicchio M, Boscaro V, Goyal P, Friemann R, Rolando B, Bagnati R, Adinolfi S, Oliaro-Bosso S, Boschi D. (2019) Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. ACS medicinal chemistry letters 10(4) 437-443 [DOI  PMID]

Rosa AC, Benetti E, Gallicchio M, Boscaro V, Cangemi L, Dianzani C, Miglio G. (2019) Analyzing Cysteine Site Neighbors in Proteins to Reveal Dimethyl Fumarate Targets. Proteomics 19(4) e1800301 [DOI  PMID]

Boscaro V, Boffa L, Binello A, Amisano G, Fornasero S, Cravotto G, Gallicchio M. (2018) Antiproliferative, Proapoptotic, Antioxidant and Antimicrobial Effects of Sinapis nigra L. and Sinapis alba L. Extracts. Molecules (Basel, Switzerland) 23(11) [DOI  PMID]

Lovisari M, Volpi G, Marabello D, Cadamuro S, Deagostino A, Diana E, Barge A, Gallicchio M, Boscaro V, Ghibaudi E. (2017) EPR and photophysical characterization of six bioactive oxidovanadium(IV) complexes in the conditions of in vitro cell tests. Journal of inorganic biochemistry 170 55-62 [DOI  PMID]

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. (2016) Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer research 76(15) 4504-15 [DOI  PMID]

Serpe L, Gallicchio M, Canaparo R, Dosio F. (2014) Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogenomics and personalized medicine 7 31-42 [DOI  PMID]

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. (2013) BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Molecular cancer therapeutics 12(12) 2950-61 [DOI  PMID]

Sgarbossa S, Diana E, Marabello D, Deagostino A, Cadamuro S, Barge A, Laurenti E, Gallicchio M, Boscaro V, Ghibaudi E. (2013) Synthesis, characterization and cell viability test of six vanadyl complexes with acetylacetonate derivatives. Journal of inorganic biochemistry 128 26-37 [DOI  PMID]

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404) 532-6 [DOI  PMID]

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. The Journal of clinical investigation 120(8) 2858-66 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. (2010) Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell cycle (Georgetown, Tex.) 9(1) 20-1 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America 105(52) 20864-9 [DOI  PMID]

Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C. (2008) Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Laboratory investigation; a journal of technical methods and pathology 88(10) 1038-48 [DOI  PMID]

Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C. (2009) Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (Augusta, Ga.) 31(3) 267-74 [DOI  PMID]

Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, Castiglia S, Danni O, Murch O, Dianzani C, Aragno M, Fantozzi R. (2008) Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock (Augusta, Ga.) 30(3) 299-307 [DOI  PMID]

Murch O, Abdelrahman M, Collino M, Gallicchio M, Benetti E, Mazzon E, Fantozzi R, Cuzzocrea S, Thiemermann C. (2008) Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Critical care medicine 36(2) 550-9 [DOI  PMID]

Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. (2006) Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free radical biology & medicine 41(4) 579-89 [DOI  PMID]

Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, Panzanelli P, Fantozzi R. (2006) Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. British journal of pharmacology 148(5) 648-56 [DOI  PMID]

Dianzani C, Collino M, Gallicchio M, Di Braccio M, Roma G, Fantozzi R. (2006) Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. Journal of inflammation (London, England) 3 4 [DOI  PMID]

Dianzani C, Collino M, Gallicchio M, Samaritani S, Signore G, Menicagli R, Fantozzi R. (2006) Evaluation of in-vitro anti-inflammatory activity of some 2-alkyl-4,6-dimethoxy-1,3,5-triazines. The Journal of pharmacy and pharmacology 58(2) 219-26 [DOI  PMID]

Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R. (2006) Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. British journal of pharmacology 147(6) 681-9 [DOI  PMID]

Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R. (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European journal of pharmacology 530(1-2) 70-80 [DOI  PMID]

Grossini E, Avanzi G, Gallicchio M, Molinari C, Vacca G, Bellomo G. (2005) Regulation of Ca2+ movements by cyclovirobuxine D in ECV304 endothelial cells. Pharmacological research 52(2) 154-61 [DOI  PMID]

Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F. (2005) Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105(5) 1970-6 [DOI  PMID]

Guidetti F, Grazioli S, Capelli F, Marini C, Gallicchio M, De Micheli D, Castello L, Sainaghi PP, Fra GP, Saglio G, Avanzi GC. (2004) Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes. Haematologica 89(1) 21-8 [PMID]

Courses

• Chemioterapia antitumorale, terapie di supporto e palliative (SSFO) - anno solare 2022/2023 (STF0156)
  Corsi di studio in
  Farmacia - Chimica e tecnologia farmaceutiche
• Farmacogenetica e farmacogenomica (STF0037)
  Corsi di studio in
  Farmacia - Chimica e tecnologia farmaceutiche
• Farmacogenetica e farmacogenomica (SSFO) - anno solare 2022/2023 (STF0117)
  Corsi di studio in
  Farmacia - Chimica e tecnologia farmaceutiche
• Farmacologia e Chemioterapia (STF0055)
  Corsi di studio in
  Farmacia - Chimica e tecnologia farmaceutiche

Research topics

• Pharmacological characterization of cannabinoids and cannabidiol-derived compounds in human cell lines

• Pharmacological characterization of new inhibitors of NLRP3 activation in differentiated THP-1
• Characterization of dual compounds with inhibitory activity on EGFR on coloncancer cell lines harboring different mutations on EGFR signaling pathway
• Evaluation of toxic effects of drug contaminants present in Antarctic-seawater on different type of cell lines
• Ecotoxicological evaluationof effects of Organic UV filters on different type of cell lines
• Evaluation of pharmacological activity of AKR1C inhibitors on colon cancer tumor cell lines, alone or in association with anticancer drugs used in the treatment of colorectal cancer

Research groups

• "Farmacogenomica tumorale"

Research projects

• Characterization, mechanism of action and structure-property relationship studies of new V(IV)complexes as potential anticancer agents. [VIVA]
• Understanding the molecular bases of secondary resistance to EGFR targeted therapies in colorectal cancer
• Contaminanti emergenti nel Mare di Ross: distribuzione, sorgenti e rischi ecorossicologici

Academic bodies

• Commissione per gli orari delle lezioni
• Commissione per l'orientamento, il tutorato e il placement
• Consiglio di Dipartimento
• Giunta

Office hours